Molecular Target Synopsis
Domains and Structures
Drugs and Clinical Candidates
Ligand Efficiency Plot
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
Germline Genetics

ACTR3B (Q9P1U1) - Overview - Molecular Target Synopsis


ACTR3B, Actin-related protein 3B
UniProt Q9P1U1

Also Known as ARP3B_HUMAN, ACTR3B, ARP11, ARP4

Plays a role in the organization of the actin cytoskeleton. May function as ATP-binding component of the Arp2/3 complex which is involved in regulation of actin polymerization and together with an activating nucleation-promoting factor (NPF) mediates the formation of branched actin networks. May decrease the metastatic potential of tumors. Interacts with the Arp2/3 complex composed of ARP2, ARP3, ARPC1B, ARPC1B/p41-ARC, ARPC2/p34-ARC, ARPC3/p21-ARC, ARPC4/p20-ARC and ARPC5/p16-ARC.

Isoforms / Transcripts (Protein Coding)

Sub-cellular localization

UniProt: ACTR3B is active in the following subcellular-locations: cell projection, cytoplasm, cytoskeleton.
GO terms: ACTR3B is active in the following subcellular-locations: Arp2/3 protein complex, cell projection, cytoplasm, extracellular exosome.

GO terms

Gene Copy Number Variation

In COSMIC - Cell Lines Project ACTR3B has gain in 4 cell-lines, loss in 4 cell-lines and no signal in 997 cell-lines. (see details)

Gene Expression

In NCI60, the highest expressing cell lines are: HOP_92, K_562, SR

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: HOP-92, NCI-H1770, NCI-H1930

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: SK-N-SH, NHLF, HSMM

(see details)

3D Structures

At greater than 90% identity similarity to ACTR3B there are:
20 structures (22 chains) solved
13 are solved in complex with at least one small molecule ligand

(see details)
Molecular Target 3D Synopsis

Screening and Chemistry

ACTR3B has been screened with compounds ( bioactivities). (see details)